Journal
MOLECULAR IMMUNOLOGY
Volume 56, Issue 3, Pages 191-198Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.molimm.2013.06.002
Keywords
Properdin; Alternative pathway; C3 glomerulopathy; Complement therapeutics
Categories
Funding
- NIAID NIH HHS [R21 AI103965, R01 AI044970, R01 AI085596, R01 AI049344] Funding Source: Medline
- NIGMS NIH HHS [R01 GM092108] Funding Source: Medline
Ask authors/readers for more resources
The plasma protein properdin is the only known positive regulator of complement activation. Although regarded as an initiator of the alternative pathway of complement activation at the time of its discovery more than a half century ago, the role and mechanism of action of properdin in the complement cascade has undergone significant conceptual evolution since then. Despite the long history of research on properdin, however, new insight and unexpected findings on the role of properdin in complement activation, pathogen infection and host tissue injury are still being revealed by ongoing investigations. In this article, we provide a brief review on recent studies that shed new light on properdin biology, focusing on the following three topics: (1) its role as a pattern recognition molecule to direct and trigger complement activation, (2) its context-dependent requirement in complement activation on foreign and host cell surfaces, and (3) its involvement in alternative pathway complement-mediated immune disorders and considerations of properdin as a potential therapeutic target in human diseases. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available